Abstract
A recent paper by Grutters et al makes the case for early health economic modeling in the development of health technologies. A number of examples of the value of early modeling are given, with analyses being performed at different stages in the development of several non-drug health technologies. This commentary acknowledges the contribution of the paper by Grutters et al and argues for an iterative and integrated approach to early modeling, assessing the cost-effectiveness of the technology, the value of future research and the interaction with the manufacturer’s pricing and revenue expectations.
Original language | English |
---|---|
Number of pages | 3 |
Journal | International Journal of Health Policy and Management |
Early online date | 1 Dec 2019 |
DOIs | |
Publication status | E-pub ahead of print - 1 Dec 2019 |